Through the Enabling Drug Discovery (EDD) initiative, the combined capabilities of SciLifeLab DDD, CBCS and MAX IV offer academic researchers an integrated workflow for early-stage target-based drug discovery. The support includes expert support on assay design, technology transfer and hit verification, together with access to complementary discovery approaches such as

• AI-assisted in silico screening for small molecules
• High-throughput screening (HTS) for small molecules
• Selection for small molecule binders from DNA-encoded compound libraries (DEL)
• Fragment screening (crystallographic screening at MAX IV and by NMR at CBCS)
• Selection for human antibody fragments from Phage display libraries
• Design and synthesis of custom-made oligonucleotide libraries

Principal investigators who successfully co-develop and validate suitable assays will be offered the opportunity to screen for potential therapeutic candidates. The resulting hits and data can provide a strong foundation for further scientific investigation and subsequent applications to SciLifeLab’s CBCS and Drug Discovery and Development (DDD) platform.

Read more about the requirements to start drug discovery projects here: https://pubmed.ncbi.nlm.nih.gov/33199880/

If you have questions about the call please contact us by email:

• DDD: dddprojectproposal@scilifelab.se
• CBCS: anna-lena.gustavsson@ki.se
• MAX IV – FragMAX: Tobias.Krojer@maxiv.lu.se

For information about the involved platforms please visit our websites:

https://www.scilifelab.se/units/ddd-platform/

https://www.cbcs.se/

https://www.maxiv.lu.se/beamlines-accelerators/science-initiatives/fragmax-crystallographic-fragment-screening/

This call is open for scientists with a doctoral degree employed at a Swedish university or higher institution. English should be used when filling out this application. You are responsible for ensuring that the application is complete. Incomplete applications will not be processed.